-
Je něco špatně v tomto záznamu ?
The role of vascular biomarkers for primary and secondary prevention. A position paper from the European Society of Cardiology Working Group on peripheral circulation: Endorsed by the Association for Research into Arterial Structure and Physiology (ARTERY) Society
C. Vlachopoulos, P. Xaplanteris, V. Aboyans, M. Brodmann, R. Cífková, F. Cosentino, M. De Carlo, A. Gallino, U. Landmesser, S. Laurent, J. Lekakis, DP. Mikhailidis, KK. Naka, AD. Protogerou, D. Rizzoni, A. Schmidt-Trucksäss, L. Van Bortel, T....
Jazyk angličtina Země Irsko
Typ dokumentu časopisecké články, přehledy
- MeSH
- analýza nákladů a výnosů MeSH
- arteriae carotides ultrasonografie MeSH
- biologické markery krev metabolismus MeSH
- C-reaktivní protein metabolismus MeSH
- hemodynamika MeSH
- intimomediální šíře tepenné stěny MeSH
- kardiologie normy MeSH
- kardiovaskulární nemoci krev diagnóza MeSH
- lidé MeSH
- primární prevence MeSH
- riziko MeSH
- rozhodování MeSH
- sekundární prevence MeSH
- společnosti lékařské MeSH
- stárnutí MeSH
- tlakový index kotník-paže MeSH
- tuhost cévní stěny MeSH
- ultrasonografie MeSH
- výsledek terapie MeSH
- výzkumný projekt MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- přehledy MeSH
- Geografické názvy
- Evropa MeSH
While risk scores are invaluable tools for adapted preventive strategies, a significant gap exists between predicted and actual event rates. Additional tools to further stratify the risk of patients at an individual level are biomarkers. A surrogate endpoint is a biomarker that is intended as a substitute for a clinical endpoint. In order to be considered as a surrogate endpoint of cardiovascular events, a biomarker should satisfy several criteria, such as proof of concept, prospective validation, incremental value, clinical utility, clinical outcomes, cost-effectiveness, ease of use, methodological consensus, and reference values. We scrutinized the role of peripheral (i.e. not related to coronary circulation) noninvasive vascular biomarkers for primary and secondary cardiovascular disease prevention. Most of the biomarkers examined fit within the concept of early vascular aging. Biomarkers that fulfill most of the criteria and, therefore, are close to being considered a clinical surrogate endpoint are carotid ultrasonography, ankle-brachial index and carotid-femoral pulse wave velocity; biomarkers that fulfill some, but not all of the criteria are brachial ankle pulse wave velocity, central haemodynamics/wave reflections and C-reactive protein; biomarkers that do no not at present fulfill essential criteria are flow-mediated dilation, endothelial peripheral arterial tonometry, oxidized LDL and dysfunctional HDL. Nevertheless, it is still unclear whether a specific vascular biomarker is overly superior. A prospective study in which all vascular biomarkers are measured is still lacking. In selected cases, the combined assessment of more than one biomarker may be required.
Cardiology Department Klinikum Wels Grieskirchen Wels Austria
Cardiology Unit Department of Medicine Karolinska University Hospital Solna 171 76 Stockholm Sweden
Clinica Medica Department of Clinical and Experimental Sciences University of Brescia Brescia Italy
Department of Angiology University Hospital Graz 8036 Graz Austria
Department of Cardiology Athens University Medical School Attikon University Hospital Athens Greece
Department of Cardiology Charité Universitätsmedizin Berlin 12203 Berlin Germany
Department of Cardiology Dupuytren University Hospital Limoges France
Department of Cardiology Tokyo Medical University 160 0023 Tokyo Japan
Department of Cardiology University of Ioannina Medical School Ioannina Greece
Department of Cardiology Wales Heart Research Institute Cardiff CF14 4XN United Kingdom
Department of Vascular Surgery Rigshospitalet University of Copenhagen Denmark
Division of Vascular Medicine Ospedale San Giovanni 6500 Bellinzona Switzerland
Heymans Institute of Pharmacology Ghent University 9000 Ghent Belgium
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc16020620
- 003
- CZ-PrNML
- 005
- 20160725103236.0
- 007
- ta
- 008
- 160722s2015 ie f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.atherosclerosis.2015.05.007 $2 doi
- 024 7_
- $a 10.1016/j.atherosclerosis.2015.05.007 $2 doi
- 035 __
- $a (PubMed)26117398
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ie
- 100 1_
- $a Vlachopoulos, Charalambos $u Peripheral Vessels Unit, 1st Department of Cardiology, Athens University Medical School, Hippokration Hospital, Athens, Greece.
- 245 14
- $a The role of vascular biomarkers for primary and secondary prevention. A position paper from the European Society of Cardiology Working Group on peripheral circulation: Endorsed by the Association for Research into Arterial Structure and Physiology (ARTERY) Society / $c C. Vlachopoulos, P. Xaplanteris, V. Aboyans, M. Brodmann, R. Cífková, F. Cosentino, M. De Carlo, A. Gallino, U. Landmesser, S. Laurent, J. Lekakis, DP. Mikhailidis, KK. Naka, AD. Protogerou, D. Rizzoni, A. Schmidt-Trucksäss, L. Van Bortel, T. Weber, A. Yamashina, R. Zimlichman, P. Boutouyrie, J. Cockcroft, M. O'Rourke, JB. Park, G. Schillaci, H. Sillesen, RR. Townsend,
- 520 9_
- $a While risk scores are invaluable tools for adapted preventive strategies, a significant gap exists between predicted and actual event rates. Additional tools to further stratify the risk of patients at an individual level are biomarkers. A surrogate endpoint is a biomarker that is intended as a substitute for a clinical endpoint. In order to be considered as a surrogate endpoint of cardiovascular events, a biomarker should satisfy several criteria, such as proof of concept, prospective validation, incremental value, clinical utility, clinical outcomes, cost-effectiveness, ease of use, methodological consensus, and reference values. We scrutinized the role of peripheral (i.e. not related to coronary circulation) noninvasive vascular biomarkers for primary and secondary cardiovascular disease prevention. Most of the biomarkers examined fit within the concept of early vascular aging. Biomarkers that fulfill most of the criteria and, therefore, are close to being considered a clinical surrogate endpoint are carotid ultrasonography, ankle-brachial index and carotid-femoral pulse wave velocity; biomarkers that fulfill some, but not all of the criteria are brachial ankle pulse wave velocity, central haemodynamics/wave reflections and C-reactive protein; biomarkers that do no not at present fulfill essential criteria are flow-mediated dilation, endothelial peripheral arterial tonometry, oxidized LDL and dysfunctional HDL. Nevertheless, it is still unclear whether a specific vascular biomarker is overly superior. A prospective study in which all vascular biomarkers are measured is still lacking. In selected cases, the combined assessment of more than one biomarker may be required.
- 650 _2
- $a stárnutí $7 D000375
- 650 _2
- $a tlakový index kotník-paže $7 D055109
- 650 _2
- $a biologické markery $x krev $x metabolismus $7 D015415
- 650 _2
- $a C-reaktivní protein $x metabolismus $7 D002097
- 650 _2
- $a kardiologie $x normy $7 D002309
- 650 _2
- $a kardiovaskulární nemoci $x krev $x diagnóza $7 D002318
- 650 _2
- $a arteriae carotides $x ultrasonografie $7 D002339
- 650 _2
- $a intimomediální šíře tepenné stěny $7 D059168
- 650 _2
- $a analýza nákladů a výnosů $7 D003362
- 650 _2
- $a rozhodování $7 D003657
- 650 _2
- $a hemodynamika $7 D006439
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a primární prevence $7 D011322
- 650 _2
- $a výzkumný projekt $7 D012107
- 650 _2
- $a riziko $7 D012306
- 650 _2
- $a sekundární prevence $7 D055502
- 650 _2
- $a společnosti lékařské $7 D012955
- 650 _2
- $a výsledek terapie $7 D016896
- 650 _2
- $a ultrasonografie $7 D014463
- 650 _2
- $a tuhost cévní stěny $7 D059289
- 651 _2
- $a Evropa $7 D005060
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Xaplanteris, Panagiotis $u Peripheral Vessels Unit, 1st Department of Cardiology, Athens University Medical School, Hippokration Hospital, Athens, Greece.
- 700 1_
- $a Aboyans, Victor $u Department of Cardiology, Dupuytren University Hospital, Limoges, France. $7 gn_A_00000689
- 700 1_
- $a Brodmann, Marianne $u Department of Angiology, University Hospital Graz, 8036 Graz, Austria.
- 700 1_
- $a Cífková, Renata $u Department of Cardiology and Angiology, First Faculty of Medicine, Charles University, Prague, Czech Republic.
- 700 1_
- $a Cosentino, Francesco $u Cardiology Unit, Department of Medicine, Karolinska University Hospital, Solna, 171 76 Stockholm, Sweden.
- 700 1_
- $a De Carlo, Marco $u Cardiac Catheterization Laboratory, Cardiothoracic and Vascular Department, Ospedale Cisanello, 56124 Pisa, Italy.
- 700 1_
- $a Gallino, Augusto $u Division of Vascular Medicine, Ospedale San Giovanni, 6500 Bellinzona, Switzerland.
- 700 1_
- $a Landmesser, Ulf $u Department of Cardiology, Charité - Universitätsmedizin Berlin (CBF), 12203 Berlin, Germany.
- 700 1_
- $a Laurent, Stéphane $u Service de Pharmacologie and INSERM U 970, Université Paris-Descartes, Assistance Publique Hôpitaux de Paris, Hôpital Européen Georges Pompidou, 75015 Paris, France.
- 700 1_
- $a Lekakis, John $u 2(nd) Department of Cardiology, Athens University Medical School, Attikon University Hospital, Athens, Greece.
- 700 1_
- $a Mikhailidis, Dimitri P $u Department of Clinical Biochemistry, Royal Free Hospital Campus, University College London Medical School, University College London (UCL), London NW3 2QG, United Kingdom.
- 700 1_
- $a Naka, Katerina K $u 2(nd) Department of Cardiology, University of Ioannina Medical School, Ioannina, Greece.
- 700 1_
- $a Protogerou, Athanasios D $u Hypertension Unit & Cardiovascular Research Laboratory, 1st Department of Internal & Propedeutic Medicine, Laiko General Hospital, National & Kapodistrian University of Athens, Greece.
- 700 1_
- $a Rizzoni, Damiano $u Clinica Medica, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy.
- 700 1_
- $a Schmidt-Trucksäss, Arno $u Department of Sport, Exercise and Health, Division Sports and Exercise Medicine, University of Basel, 4052 Basel, Switzerland.
- 700 1_
- $a Van Bortel, Luc $u Heymans Institute of Pharmacology, Ghent University, 9000 Ghent, Belgium.
- 700 1_
- $a Weber, Thomas $u Cardiology Department, Klinikum Wels-Grieskirchen, Wels, Austria.
- 700 1_
- $a Yamashina, Akira $u Department of Cardiology, Tokyo Medical University, 160-0023 Tokyo, Japan.
- 700 1_
- $a Zimlichman, Reuven $u Department of Medicine and Hypertension Institute, Brunner Institute for Cardiovascular Research, Sackler Faculty of Medicine, Tel-Aviv University, The E. Wolfson Medical Center, Holon 58100, Israel.
- 700 1_
- $a Boutouyrie, Pierre $u Department of Pharmacology and INSERM U970, Assistance Publique Hôpitaux de Paris, Université Paris Descartes, Paris 75015, France.
- 700 1_
- $a Cockcroft, John $u Department of Cardiology, Wales Heart Research Institute, Cardiff CF14 4XN, United Kingdom.
- 700 1_
- $a O'Rourke, Michael $u St Vincent's Clinic, University of New South Wales, Victor Chang Cardiac Research Institute, Sydney, Australia.
- 700 1_
- $a Park, Jeong Bae $u Department of Medicine/Cardiology, Cheil General Hospital, Dankook University College of Medicine, Seoul 100-380, Republic of Korea.
- 700 1_
- $a Schillaci, Giuseppe $u Unit of Internal Medicine, Department of Medicine, University of Perugia and Terni University Hospital, Terni, Italy.
- 700 1_
- $a Sillesen, Henrik $u Department of Vascular Surgery, Rigshospitalet, University of Copenhagen, Denmark.
- 700 1_
- $a Townsend, Raymond R $u Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Pennsylvania, Philadelphia, United States.
- 773 0_
- $w MED00009284 $t Atherosclerosis $x 1879-1484 $g Roč. 241, č. 2 (2015), s. 507-32
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/26117398 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20160722 $b ABA008
- 991 __
- $a 20160725103454 $b ABA008
- 999 __
- $a ok $b bmc $g 1155290 $s 945148
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2015 $b 241 $c 2 $d 507-32 $e 20150516 $i 1879-1484 $m Atherosclerosis $n Atherosclerosis $x MED00009284
- LZP __
- $a Pubmed-20160722
